Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Anthony Lima

1PUBLICATIONS

19CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Jul 03, 2025

RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.

Ashley V DiMarco, Mirunalini Ravichandran, Jeff Lau

Pageof 1

Frequent Collaborators

1 joint publications

Ashley V DiMarco

1 joint publications

Mirunalini Ravichandran

1 joint publications

Jeff Lau

1 joint publications

Jennifer Lacap

1 joint publications

Pablo Saenz-Lopez Larrocha

1 joint publications

Eva Lin

1 joint publications

Julie Weng

1 joint publications

Luca Gerosa

1 joint publications

Thomas Hunsaker

1 joint publications

Yang Xiao

Frequent Collaborators

1 joint publications

Ashley V DiMarco

1 joint publications

Mirunalini Ravichandran

1 joint publications

Jeff Lau

1 joint publications

Jennifer Lacap

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos